Furthermore, the safety data from real world population‐based studies17, 18 on intravitreal anti‐VEGFs agents (ranibizumab, aflibercept and bevacizumab) in patients with AMD, found no consistent evidence that intravitreal anti‐VEGF therapy was associated with increased risk of stroke, MI, or death. This evidence concerns the gene VEGFA and age-related macular degeneration.